In today’s session Cempra Inc (CEMP) registered an unusually high (191) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the January, 2017 call, expecting serious CEMP increase. With 191 contracts traded and 8594 open interest for the Jan, 17 contract, it seems this is a quite bullish bet. The option with symbol: CEMP170120C00020000 closed last at: $3.8 or 45.7% down. About 686,257 shares traded hands. Cempra Inc (NASDAQ:CEMP) has risen 11.36% since March 30, 2016 and is uptrending. It has outperformed by 8.35% the S&P500.
Cempra Inc (NASDAQ:CEMP) Ratings Coverage
Out of 9 analysts covering Cempra (NASDAQ:CEMP), 8 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 89% are positive. Cempra has been the topic of 13 analyst reports since July 30, 2015 according to StockzIntelligence Inc. The company was maintained on Friday, October 23 by Stifel Nicolaus. The rating was maintained by TH Capital on Monday, October 19 with “Buy”. The rating was initiated by Janney Capital with “Buy” on Friday, December 11. Jefferies maintained it with “Buy” rating and $40 target price in Tuesday, August 2 report. On Thursday, July 30 the stock rating was maintained by Needham with “Buy”. Morgan Stanley initiated the stock with “Equal-Weight” rating in Thursday, August 13 report. The stock of Cempra Inc (NASDAQ:CEMP) earned “Buy” rating by Roth Capital on Tuesday, June 7. Raymond James initiated the shares of CEMP in a report on Tuesday, September 13 with “Outperform” rating. The rating was maintained by Stifel Nicolaus on Friday, June 24 with “Buy”. The rating was upgraded by Morgan Stanley to “Overweight” on Monday, November 16.
According to Zacks Investment Research, “Cempra Holdings, LLC is a pharmaceutical company engaged in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, skin and skin structure infections and to target the growing problem of antimicrobial resistance. Cempra Holdings, LLC is headquartered in Chapel Hill, North Carolina.”
Insitutional Activity: The institutional sentiment increased to 2.27 in 2016 Q2. Its up 0.72, from 1.55 in 2016Q1. The ratio improved, as 10 funds sold all Cempra Inc shares owned while 23 reduced positions. 14 funds bought stakes while 61 increased positions. They now own 39.80 million shares or 3.16% more from 38.58 million shares in 2016Q1.
The Montana-based Da Davidson Com has invested 0% in Cempra Inc (NASDAQ:CEMP). Ameriprise Financial accumulated 0% or 57,160 shares. Northern Tru Corp holds 469,725 shares or 0% of its portfolio. Moreover, Wasatch Advisors has 0.61% invested in Cempra Inc (NASDAQ:CEMP) for 2.43 million shares. Pnc Fincl Group has 148 shares for 0% of their US portfolio. Pennsylvania Tru Company last reported 70,158 shares in the company. Quantitative Inv Limited Liability Corp last reported 16,300 shares in the company. Great West Life Assurance Communication Can has invested 0% of its portfolio in Cempra Inc (NASDAQ:CEMP). The United Kingdom-based Abingworth Limited Liability Partnership has invested 6.63% in Cempra Inc (NASDAQ:CEMP). Credit Suisse Ag accumulated 52,074 shares or 0% of the stock. Parametric Assocs Lc, a Washington-based fund reported 17,390 shares. Barclays Plc holds 785 shares or 0% of its portfolio. Rhenman Partners Asset Mngmt Ab, a Sweden-based fund reported 171,000 shares. Kcg Holding has 0.01% invested in the company for 27,553 shares. Sei Invests last reported 0.01% of its portfolio in the stock.
Cempra, Inc. is a clinical-stage pharmaceutical company. The company has a market cap of $948.13 million. The Firm is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. It currently has negative earnings. The Company’s lead product, solithromycin , is being developed in oral capsules, intravenous (IV), and suspension formulations, for the treatment of community-acquired bacterial pneumonia (CABP), as well as for the treatment of gonorrhea and other indications.
CEMP Company Profile
Cempra, Inc., incorporated on May 16, 2008, is a clinical-stage pharmaceutical company. The Firm is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company’s lead product, solithromycin (CEM-101), is being developed in oral capsules, intravenous (IV), and suspension formulations, for the treatment of community-acquired bacterial pneumonia (CABP), as well as for the treatment of gonorrhea and other indications. The Firm also focuses on developing Taksta, which is an antibiotic known as fusidic acid, and is indicated as an oral treatment of acute bacterial skin and skin structure infections (ABSSSI).
More important recent Cempra Inc (NASDAQ:CEMP) news were published by: Fool.com which released: “Why Cempra Inc Got Crushed Today” on October 28, 2016, also Seekingalpha.com published article titled: “Cempra Poised To Become The Next Antibiotic Buyout”, Schaeffersresearch.com published: “Option Bears Bombard Cempra Inc (CEMP) Amid Earnings Selloff” on October 28, 2016. More interesting news about Cempra Inc (NASDAQ:CEMP) was released by: Seekingalpha.com and their article: “Cempra, Inc. And Solithera Are Still Undervalued Amid Upcoming Catalysts” with publication date: October 11, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.